It is time to address fear of cancer recurrence in family caregivers: protocol for the feasibility and acceptability of a randomized pilot study of the online version of the Family Caregiver-Fear Of Recurrence Therapy (FC-FORT).

Jani Lamarche, Rinat Nissim, Jonathan Avery, Jiahui Wong, Christine Maheu, Sylvie D Lambert, Andrea M Laizner, Jennifer Jones, Mary Jane Esplen, Sophie Lebel
Author Information
  1. Jani Lamarche: School of Psychology, University of Ottawa, 136 Jean-Jacques-Lussier Private, Ottawa, ON, K1N 9A8, Canada. jlama023@uottawa.ca. ORCID
  2. Rinat Nissim: Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  3. Jonathan Avery: Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  4. Jiahui Wong: Cancer Chat De Souza Institute, 222 St Patrick Street, Office 503, Toronto, ON, M5T 1V4, Canada.
  5. Christine Maheu: Ingram School of Nursing, McGill University, 680 Sherbrooke West, Suite 1800, Montreal, QC, H3A 2M7, Canada.
  6. Sylvie D Lambert: Ingram School of Nursing, McGill University, 680 Sherbrooke West, Suite 1800, Montreal, QC, H3A 2M7, Canada.
  7. Andrea M Laizner: Ingram School of Nursing, McGill University, 680 Sherbrooke West, Suite 1800, Montreal, QC, H3A 2M7, Canada.
  8. Jennifer Jones: Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  9. Mary Jane Esplen: Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, 250 College Street, Toronto, Canada.
  10. Sophie Lebel: School of Psychology, University of Ottawa, 136 Jean-Jacques-Lussier Private, Ottawa, ON, K1N 9A8, Canada.

Abstract

BACKGROUND: fear of cancer recurrence (FCR) is common, persistent, and is associated with lower quality of life, impaired functioning, and psychological distress in cancer patients. Studies suggest that family caregivers of cancer patients experience equal or greater levels of FCR than patients themselves. In the past 5 years, several interventions have demonstrated their ability to reduce FCR among cancer patients and in patient-caregiver dyads. However, to date, no intervention exists to individually target family caregiver's FCR. The aims of the proposed pilot study are to (1) assess the feasibility and acceptability of the newly adapted Family Caregiver-Fear of Recurrence Therapy (FC-FORT) intervention to inform a larger randomized control trial study, and (2) estimate the clinical significance of FC-FORT. Initial evaluation of FC-FORT revealed high user satisfaction and usability.
METHODS: A parallel, two-group, pilot randomized controlled trial comparing FC-FORT to a waitlist control (care as usual) will be conducted. Participant inclusion criteria are (a) women family caregivers taking care of adult cancer patients (no recurrence), (b) experiencing clinical levels of FCR, (c) access to a computer/internet connection, and (d) living in Canada. participants (n���=���36) will be recruited at Ottawa and Toronto hospitals, previous study Participant pools, through social media and community partners across Canada. participants in the intervention group will complete the FC-FORT intervention (7 consecutive weeks of virtual group therapy and homework). participants in the control group will be offered the intervention after their participation in the study. All participants will be asked to complete questionnaire packages at baseline (T0), immediately post-intervention (7 weeks; T1) and at 3-months post-intervention (T2). Feasibility (e.g., recruitment, allocation, fidelity), acceptability (e.g., dropout, completion, satisfaction) and clinical significance of secondary outcomes will be evaluated (i.e., FCR illness uncertainty). participants in the intervention group will be asked to complete measures of group cohesion and therapeutic alliance and take part in a semi-structured exit interview exploring their overall experience with FC-FORT.
DISCUSSION: This project will evaluate the acceptability and feasibility of the newly adapted FC-FORT to inform a larger trial.
TRIAL REGISTRATION: NCT, NCT05441384. Registered July 1st, 2022, https://classic.
CLINICALTRIALS: gov/ct2/show/NCT05441384.

Keywords

Associated Data

ClinicalTrials.gov | NCT05441384

References

  1. Support Care Cancer. 2018 Aug;26(8):2751-2762 [PMID: 29500582]
  2. J Cancer Surviv. 2016 Oct;10(5):802-13 [PMID: 26899851]
  3. J Clin Oncol. 2019 Nov 1;37(31):2899-2915 [PMID: 31532725]
  4. Psychooncology. 1997 Jun;6(2):95-105 [PMID: 9205967]
  5. Psychooncology. 2017 Dec;26(12):2079-2085 [PMID: 28317267]
  6. J Cancer Surviv. 2013 Sep;7(3):300-22 [PMID: 23475398]
  7. Support Care Cancer. 2016 Aug;24(8):3265-8 [PMID: 27169703]
  8. J Med Internet Res. 2001 Apr-Jun;3(2):E20 [PMID: 11720962]
  9. Ann Behav Med. 2012 Apr;43(2):239-52 [PMID: 22037965]
  10. Front Digit Health. 2023 Aug 21;5:1129536 [PMID: 37671170]
  11. Psychooncology. 2022 Jun;31(6):879-892 [PMID: 35388525]
  12. Psychooncology. 2018 Nov;27(11):2546-2558 [PMID: 29744965]
  13. Psychooncology. 2018 Jun;27(6):1572-1579 [PMID: 29508503]
  14. J Clin Oncol. 2015 Sep 1;33(25):2763-71 [PMID: 26169621]
  15. J Cancer Surviv. 2014 Sep;8(3):485-96 [PMID: 24756313]
  16. Cancer. 2017 May 15;123(6):906-910 [PMID: 28207157]
  17. Psychooncology. 2018 Jun;27(6):1580-1588 [PMID: 29508471]
  18. J Health Commun. 2015;20(3):328-42 [PMID: 25629218]
  19. Eur J Cancer Care (Engl). 2015;24(1):50-9 [PMID: 24761985]
  20. J Psychosoc Oncol. 2015;33(3):297-309 [PMID: 25751193]
  21. CA Cancer J Clin. 2010 Sep-Oct;60(5):317-39 [PMID: 20709946]
  22. Qual Health Res. 2005 Nov;15(9):1277-88 [PMID: 16204405]
  23. J Med Internet Res. 2006 Jun 23;8(2):e10 [PMID: 16867965]
  24. J Anxiety Disord. 2008;22(3):355-70 [PMID: 17544253]
  25. J Pain Symptom Manage. 2007 Sep;34(3):294-304 [PMID: 17572056]
  26. Health Psychol. 2023 Mar;42(3):182-194 [PMID: 36862474]
  27. Palliat Support Care. 2013 Jun;11(3):231-52 [PMID: 23046977]
  28. Int J Nurs Stud. 2022 Mar;127:104179 [PMID: 35124473]
  29. J Consult Clin Psychol. 2000 Dec;68(6):957-64 [PMID: 11142548]
  30. BMC Cancer. 2018 Mar 2;18(1):244 [PMID: 29499663]
  31. Eur J Oncol Nurs. 2015 Apr;19(2):113-9 [PMID: 25538036]
  32. J Cancer Surviv. 2022 Dec;16(6):1184-1219 [PMID: 34762248]
  33. Nurse Educ Today. 2017 Sep;56:29-34 [PMID: 28651100]
  34. J Cancer Surviv. 2015 Sep;9(3):481-91 [PMID: 25603948]
  35. Front Psychol. 2017 May 23;8:834 [PMID: 28596746]
  36. J Anxiety Disord. 2007;21(1):105-17 [PMID: 16647833]
  37. Psychooncology. 2007 Mar;16(3):214-23 [PMID: 16906624]
  38. Internet Interv. 2019 Aug 15;18:100265 [PMID: 31890618]
  39. Br J Cancer. 2002 Jan 7;86(1):43-50 [PMID: 11857010]
  40. BMJ. 2013 Jan 08;346:e7586 [PMID: 23303884]
  41. J Med Internet Res. 2018 Feb 02;20(2):e25 [PMID: 29396387]
  42. Am J Pharm Educ. 2020 Jan;84(1):7113 [PMID: 32292185]
  43. Bone Marrow Transplant. 2014 Sep;49(9):1217-22 [PMID: 25000458]
  44. Support Care Cancer. 2018 Sep;26(9):3003-3011 [PMID: 29546528]
  45. Qual Life Res. 2012 Apr;21(3):517-25 [PMID: 21691928]
  46. J Cancer Educ. 2022 Dec;37(6):1634-1640 [PMID: 33783762]
  47. J Gynecol Oncol. 2017 Nov;28(6):e72 [PMID: 28758378]
  48. Perspect Psychiatr Care. 2013 Jan;49(1):58-64 [PMID: 23293998]
  49. Psychooncology. 2020 Jan;29(1):38-48 [PMID: 31702839]
  50. BMC Cancer. 2016 Apr 25;16:291 [PMID: 27112319]
  51. Am J Public Health. 2012 Jul;102(7):1267-73 [PMID: 22594719]
  52. Psychooncology. 2018 Nov;27(11):2594-2601 [PMID: 30180279]
  53. Cancer. 2016 Jul 1;122(13):1987-95 [PMID: 26991807]
  54. Encephale. 2002 Jul-Aug;28(4):298-309 [PMID: 12232539]
  55. Psychooncology. 2003 Sep;12(6):532-46 [PMID: 12923794]
  56. Pilot Feasibility Stud. 2016 Jul 19;2:35 [PMID: 27976755]
  57. Oral Oncol. 2012 Jan;48(1):18-25 [PMID: 22154127]
  58. Psychooncology. 1997 Mar;6(1):25-33 [PMID: 9126713]
  59. J Clin Epidemiol. 2010 Aug;63(8):e1-37 [PMID: 20346624]
  60. Image J Nurs Sch. 1988 Winter;20(4):225-32 [PMID: 3203947]

Word Cloud

Created with Highcharts 10.0.0FC-FORTwillcancerinterventionstudyFCRpatientsgrouprecurrencefamilyacceptabilityParticipantspilotfeasibilityrandomizedcontroltrialclinicalcompleteeFearcaregiversexperiencelevelsnewlyadaptedFamilyCaregiver-FearRecurrenceTherapyinformlargersignificancesatisfactioncareCanadaaskedpost-interventiongBACKGROUND:commonpersistentassociatedlowerqualitylifeimpairedfunctioningpsychologicaldistressStudiessuggestequalgreaterpast5 yearsseveralinterventionsdemonstratedabilityreduceamongin patient-caregiverdyadsHoweverdateexistsindividuallytargetcaregiver'saimsproposed1assess2estimateInitialevaluationrevealedhighuserusabilityMETHODS:paralleltwo-groupcontrolledcomparingwaitlistusualconductedParticipantinclusioncriteriawomentakingadultbexperiencingcaccesscomputer/internetconnectiondlivingn���=���36recruitedOttawaTorontohospitalspreviousparticipantpoolssocialmediacommunitypartnersacross7consecutiveweeksvirtualtherapyhomeworkofferedparticipationparticipantsquestionnairepackagesbaselineT0immediately7 weeksT13-monthsT2 Feasibilityrecruitmentallocationfidelitydropoutcompletionsecondaryoutcomesevaluatedi FCRillnessuncertaintymeasurescohesiontherapeuticalliancetakepartsemi-structuredexitinterviewexploringoverallDISCUSSION:projectevaluateTRIALREGISTRATION:NCTNCT05441384RegisteredJuly1st2022https://classicCLINICALTRIALS:gov/ct2/show/NCT05441384timeaddressfearcaregivers:protocolonlineversionAcceptabilityCancerCaregiversFeasibilityPilot

Similar Articles

Cited By (1)